FibroGen (FGEN) Competitors $12.12 -0.31 (-2.45%) Closing price 03:58 PM EasternExtended Trading$12.10 -0.03 (-0.21%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock FGEN vs. RAPT, VYGR, CCCC, TNYA, TIL, MDWD, AARD, ENTA, TVGN, and CGTXShould you be buying FibroGen stock or one of its competitors? The main competitors of FibroGen include Rapt Therapeutics (RAPT), Voyager Therapeutics (VYGR), C4 Therapeutics (CCCC), Tenaya Therapeutics (TNYA), Instil Bio (TIL), MediWound (MDWD), Aardvark Therapeutics (AARD), Enanta Pharmaceuticals (ENTA), Tevogen Bio (TVGN), and Cognition Therapeutics (CGTX). These companies are all part of the "pharmaceutical products" industry. FibroGen vs. Its Competitors Rapt Therapeutics Voyager Therapeutics C4 Therapeutics Tenaya Therapeutics Instil Bio MediWound Aardvark Therapeutics Enanta Pharmaceuticals Tevogen Bio Cognition Therapeutics FibroGen (NASDAQ:FGEN) and Rapt Therapeutics (NASDAQ:RAPT) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, institutional ownership, valuation, risk, analyst recommendations, media sentiment, earnings and profitability. Which has more risk & volatility, FGEN or RAPT? FibroGen has a beta of 0.76, suggesting that its share price is 24% less volatile than the S&P 500. Comparatively, Rapt Therapeutics has a beta of -0.1, suggesting that its share price is 110% less volatile than the S&P 500. Does the media refer more to FGEN or RAPT? In the previous week, Rapt Therapeutics had 2 more articles in the media than FibroGen. MarketBeat recorded 4 mentions for Rapt Therapeutics and 2 mentions for FibroGen. FibroGen's average media sentiment score of 0.68 beat Rapt Therapeutics' score of 0.59 indicating that FibroGen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment FibroGen 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Rapt Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts prefer FGEN or RAPT? FibroGen currently has a consensus price target of $43.00, suggesting a potential upside of 254.64%. Rapt Therapeutics has a consensus price target of $21.57, suggesting a potential upside of 33.28%. Given FibroGen's higher probable upside, research analysts plainly believe FibroGen is more favorable than Rapt Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score FibroGen 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50Rapt Therapeutics 0 Sell rating(s) 5 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.50 Which has higher earnings & valuation, FGEN or RAPT? FibroGen has higher revenue and earnings than Rapt Therapeutics. FibroGen is trading at a lower price-to-earnings ratio than Rapt Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioFibroGen$7.35M6.67-$47.58M-$0.38-31.91Rapt Therapeutics$1.53M174.97-$129.87M-$14.17-1.14 Is FGEN or RAPT more profitable? Rapt Therapeutics has a net margin of 0.00% compared to FibroGen's net margin of -3.86%. FibroGen's return on equity of 0.00% beat Rapt Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets FibroGen-3.86% N/A -27.34% Rapt Therapeutics N/A -67.92%-59.59% Do institutionals & insiders hold more shares of FGEN or RAPT? 72.7% of FibroGen shares are held by institutional investors. Comparatively, 99.1% of Rapt Therapeutics shares are held by institutional investors. 3.1% of FibroGen shares are held by company insiders. Comparatively, 2.4% of Rapt Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. SummaryFibroGen beats Rapt Therapeutics on 9 of the 16 factors compared between the two stocks. Get FibroGen News Delivered to You Automatically Sign up to receive the latest news and ratings for FGEN and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding FGEN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart FGEN vs. The Competition Export to ExcelMetricFibroGenMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$49.03M$2.84B$5.81B$10.16BDividend YieldN/A56.65%5.69%4.60%P/E Ratio-31.9123.5974.6225.97Price / Sales6.67541.19454.4485.61Price / CashN/A169.2537.0859.91Price / Book-0.245.3712.156.29Net Income-$47.58M$32.95M$3.28B$270.77M7 Day Performance0.21%1.37%0.98%3.32%1 Month Performance31.08%8.33%7.19%6.40%1 Year Performance14.58%0.75%63.14%28.24% FibroGen Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)FGENFibroGen4.529 of 5 stars$12.13-2.5%$43.00+254.6%+25.4%$49.03M$7.35M-31.91570News CoverageRAPTRapt Therapeutics4.2217 of 5 stars$11.38-0.7%$21.57+89.6%+1.7%$188.20M$1.53M0.0080News CoverageVYGRVoyager Therapeutics3.9611 of 5 stars$3.36-1.2%$13.25+294.3%-30.3%$186.38M$80M-1.82100Positive NewsCCCCC4 Therapeutics2.9877 of 5 stars$2.60+2.0%$8.00+207.7%-54.5%$185.04M$35.58M-1.65150Positive NewsTNYATenaya Therapeutics3.3124 of 5 stars$1.13flat$6.25+453.1%-41.8%$184.16MN/A-1.18110Positive NewsTILInstil Bio2.6641 of 5 stars$27.00-2.3%$119.00+340.7%-19.7%$182.27MN/A-2.09410Analyst ForecastMDWDMediWound1.6388 of 5 stars$16.70-0.7%$32.25+93.1%+11.4%$180.49M$20.22M-6.3380AARDAardvark Therapeutics3.6915 of 5 stars$8.30-2.2%$32.60+292.8%N/A$180.08MN/A0.0018News CoverageENTAEnanta Pharmaceuticals4.18 of 5 stars$8.40-3.3%$21.67+157.9%-28.1%$179.57M$67.64M-1.94160Positive NewsTVGNTevogen Bio3.9082 of 5 stars$0.91+0.8%$10.00+998.9%+101.3%$179MN/A0.003CGTXCognition Therapeutics2.8314 of 5 stars$2.43-2.0%$2.83+16.6%+288.3%$178.66MN/A0.0020Short Interest ↑ Related Companies and Tools Related Companies Rapt Therapeutics Competitors Voyager Therapeutics Competitors C4 Therapeutics Competitors Tenaya Therapeutics Competitors Instil Bio Competitors MediWound Competitors Aardvark Therapeutics Competitors Enanta Pharmaceuticals Competitors Tevogen Bio Competitors Cognition Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:FGEN) was last updated on 9/12/2025 by MarketBeat.com Staff From Our PartnersForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredTrump’s Plan May Undo 1933’s Biggest Financial InjusticeTrump's Reset Can Give Birth To America's Greatest Era Yet A 90-Year cycle may end soon, creating real weal...American Hartford Gold | SponsoredGENIUS Act: The Plot to Seize Your Cash?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredThe $17B signal no one expected…After SpaceX struck a $17 billion deal with EchoStar for a block of radio frequencies, tech analyst Jeff Brown...Brownstone Research | SponsoredCollege grad makes $64,000 a monthIt's easy to feel like you've missed out on the biggest stock market boom of the century. But if you want t...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding FibroGen, Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share FibroGen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
